[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kivu Bioscience Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100634874",false,"NCT07545356","A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors","A Phase 1 Dose-Finding and Dose Optimization-Expansion Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Male or female ≥18 years of age\n* Pathologically or histologically documented diagnosis of advanced \u002F metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available\n* Adequate bone marrow, kidney, and liver function\n* Measurable disease using RECIST v1.1\n* ECOG 0 or 1\n* Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* Prior treatment with any ADC with a topoisomerase 1 inhibitor payload\n* Prior treatment with any CEACAM5 targeted therapy\n* Uncontrolled cardiovascular disease\n* Uncontrolled active Hepatitis B, Hepatitis C, or HIV infection\n* History of interstitial lung disease\n* Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start","ALL","18 Years",{"count":18,"type":19},76,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.",[25],"Solid Tumors",[27,28,29,30,31,32,33],"CEACAM5","ADC","Antibody drug conjugate","KIVU305","Colorectal cancer","CRC","Phase 1","NOT_YET_RECRUITING","2026-04-16",{"date":37,"type":38},"2026-04-22","ACTUAL",{"date":40,"type":19},"2026-06",{"date":42,"type":19},"2029-12",{"name":44,"class":45},"Kivu Bioscience Inc.","INDUSTRY",1,{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100610571","NCT07229313","A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors","A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Male or female ≥18 years of age\n* No therapy of proven efficacy exists for the tumor\n* Pathologically or histologically documented diagnosis of advanced \u002F metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available.\n* Adequate bone marrow, kidney, and liver function\n* Measurable disease using RECIST v1.1\n* ECOG 0 or 1\n* Life expectancy ≥ 3 months\n\nExclusion Criteria:\n\n* Prior treatment with any ADC with topoisomerase 1 inhibitor payload\n* Any PTK7 - targeted therapy\n* Uncontrolled cardiovascular disease\n* Active Hepatitis B, Hepatitis C, or HIV infection\n* History of interstitial lung disease\n* Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start.",{"count":18,"type":19},[22],"This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.",[57],"Advance Solid Tumors",[59,28,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,32,80,81,82,83,84],"PTK7","solid tumors","PTK-7 expression","metastatic","locally advanced","PTK7 expression","endometrial cancer","ovarian cancer","breast cancer","cervical cancer","GI\u002FGEJ adenocarcinoma","esophageal squamous cell cancer","colorectal cancer","pancreatic cancer","non-small cell lung cancer","small cell lung cancer","head and neck squamous cell carcinoma","sarcoma","OvCa","NSCLC","SCLC","PDAC","HNSCC","TNBC","triple negative breast cancer","antibody drug conjugate","RECRUITING","2026-04-14",{"date":35,"type":38},{"date":89,"type":38},"2025-11-13",{"date":91,"type":19},"2030-03-31",{"name":44,"class":45},6,""]